Prediction models for rheumatoid arthritis during diagnostic investigation: evaluation of combinations of rheumatoid factor, anti-citrullinated protein/peptide antibodies and the human leucocyte antigen-shared epitope
Authors:
- Bert Vander CruyssenBCBert Vander Cruyssen
- Ilse E A HoffmanIHIlse E A Hoffman
- Isabelle PeeneIPIsabelle Peene
- Ann UnionAUAnn Union
- Herman MielantsHMHerman Mielants
- Lydie MeheusLMLydie Meheus
- Filip De KeyserFKFilip De Keyser
- 1 March 2007
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 66 (3) , 364-369
Abstract
To calculate the probabilities for rheumatoid arthritis in a consecutive cohort of patients during diagnostic investigation. Different logistic regression models evaluating the value of human leucocyte antigen (HLA)-shared epitope determination and testing for rheumatoid factor and anti-citrullinated protein/peptide antibodies (ACPA) were fitted. 1003 consecutive patients were included in the study, presenting a new diagnostic problem for which rheumatoid arthritis was included in the differential diagnosis. All patients were tested for ACPA, rheumatoid factor and HLA-shared epitope. After 1 year, diagnoses were established: 153 patients had definite rheumatoid arthritis and 629 patients had rheumatoid arthritis excluded. Rheumatoid factor, used as a continuous marker, is useful in evaluating the probability for rheumatoid arthritis. Combined rheumatoid factor and shared epitope testing may provide additional predictive information, but combined ACPA and rheumatoid factor testing is superior. The redundancy of shared epitope testing in a model that includes ACPA testing can be explained by the high association between ACPA and shared epitope both in patients with rheumatoid arthritis and in those with non-rheumatoid arthritis. The value of rheumatoid factor testing increased if patients presented with at least one swollen joint at baseline. Valid probabilities for rheumatoid arthritis during routine diagnostic investigation were calculated, and showed that the potential additional value of shared epitope testing disappears when ACPA testing is available. Combined rheumatoid factor and ACPA testing is useful, especially when rheumatoid factor is considered as a continuous parameter reflecting an increasing probability for rheumatoid arthritis at higher rheumatoid factor titres. The value of (continuous) rheumatoid factor testing increases when the a priori chance is higher.Keywords
This publication has 33 references indexed in Scilit:
- Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope allelesAnnals of the Rheumatic Diseases, 2006
- A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA–DR (shared epitope)–restricted immune reactions to autoantigens modified by citrullinationArthritis & Rheumatism, 2005
- Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritisAnnals of the Rheumatic Diseases, 2005
- Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA–DRB1 shared epitope for antibodies to citrullinated proteinsArthritis & Rheumatism, 2005
- Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritisAnnals of the Rheumatic Diseases, 2005
- Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase as pathophysiologically relevant antigenic determinants of rheumatoid arthritis–specific humoral autoimmunityArthritis & Rheumatism, 2005
- Diagnostic Performance and Predictive Value of Rheumatoid Factor, Anti-citrullinated Peptide Antibodies, and the HLA Shared Epitope for Diagnosis of Rheumatoid ArthritisClinical Chemistry, 2005
- Diagnostic Performance and Predictive Value of Anti-citrullinated Peptide Antibodies for Diagnosis of Rheumatoid Arthritis: Toward More Accurate Detection?Clinical Chemistry, 2005
- The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritisArthritis & Rheumatism, 2000
- The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptideArthritis & Rheumatism, 2000